Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Reports Q3 revenue $12.82B, consensus $12.76B. Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered another quarter of ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis AG boosted its annual profit guidance for the third straight quarter, helped by rising sales of its blockbuster ...